Expanding Indications for IV Thrombolysis in Acute Ischemic Stroke

Since the original NINDS trial in 1995, the eligibility criteria for intravenous thrombolysis have progressively widened. Early limitations—such as narrow time windows, strict age cutoffs, and exclusion of patients with unknown onset—have given way to a more nuanced, individualized approach. The 2026 AHA/ASA guidelines consolidate decades of evidence and formally endorse tissue-based patient selection.

Updated to reflect the 2026 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke.

🔹 Bottom Line: IVT Eligibility

  • Agent: Tenecteplase 0.25 mg/kg is now equivalent to alteplase (Class 1, Level A)
  • Standard window: 0–4.5h with disabling deficits → Class 1
  • Unknown onset: DWI-FLAIR mismatch → Class 2a
  • 4.5–9h: Perfusion mismatch → Class 2a
  • 4.5–24h LVO (no EVT): Class 2b
  • Mild non-disabling: NOT recommended (Class 3: No Benefit)

🔹 2026 Key Thrombolysis Recommendations

  • Class 1 (A): Tenecteplase 0.25 mg/kg (max 25 mg) OR alteplase 0.9 mg/kg within 4.5h of symptom onset
  • Class 1 (A): IVT for disabling stroke with early ischemic changes (mild-moderate) on NCCT
  • Class 1 (B-NR): IVT recommended despite single or dual antiplatelet therapy use
  • Class 3: No Benefit (B-R): IVT NOT recommended for mild non-disabling deficits
  • Class 3: No Benefit (A): Tenecteplase 0.4 mg/kg NOT recommended

Time Windows: From 3 Hours to 24 Hours

Standard Window: 0–4.5 Hours

Current guidelines endorse IVT within 4.5 hours of stroke onset for patients with disabling deficits. This is based on NINDS (0–3h) and ECASS III (3–4.5h) trials.

2026 Update: Treatment should be initiated as quickly as possible. Do NOT delay for additional multimodal neuroimaging (CTA/MRA, CTP) when not necessary for treatment decisions (Class 1).

Unknown Onset / Wake-Up Stroke

Patients with unknown time of onset—such as wake-up strokes—are eligible if MRI mismatch (DWI positive, FLAIR negative) confirms biological onset within 4.5 hours.

  • WAKE-UP (2018): mRS 0–1 in 53.3% vs 41.8% (P = 0.02)
  • DWI lesion must be <1/3 MCA territory; no marked FLAIR signal change

2026 Guideline: Class 2a (B-R) — IVT can be beneficial within 4.5h of symptom recognition if MRI criteria met.

Extended Window: 4.5–9 Hours

EXTEND (2019) and pooled analyses used perfusion imaging to identify patients with salvageable penumbra up to 9h:

  • mRS 0–1: 35.4% vs 29.5% (aRR 1.44; P = 0.04)
  • sICH: 6.2% vs 0.9%

2026 Guideline: Class 2a (B-R) — IVT may be reasonable in 4.5–9h window OR wake-up stroke within 9h of sleep midpoint with salvageable penumbra on perfusion imaging.

Extended Window: 4.5–24 Hours (LVO)

Recent trials pushed the window further for LVO patients:

  • TRACE-III (2024): Tenecteplase in LVO without EVT; mRS 0–1: 33.0% vs 24.2% (P = 0.03)
  • TIMELESS (2024): Tenecteplase in LVO with EVT; Neutral — IVT did not add benefit when rapid EVT available
  • CHABLIS-T II (2025): Improved recanalization but no significant difference in functional outcomes

2026 Guideline: Class 2b (B-R) — In LVO patients 4.5–24h with salvageable penumbra who cannot receive or will have delayed EVT, IVT may be beneficial when directed by experts.

Patient Factors: Age, Baseline Function, Stroke Severity

Age

Guidelines no longer impose an upper age limit. Patients >80 years are eligible if otherwise appropriate. ECASS III originally excluded age >80 in the 3–4.5h window, but subsequent data and meta-analyses support treatment in elderly patients.

Preexisting Disability

Patients with preexisting disability (mRS ≥2) can receive IVT if the stroke is expected to cause new, disabling deficits. Decision-making should incorporate goals of care, functional prognosis, and patient preferences.

Stroke Severity

Severity is not an automatic exclusion:

  • Very severe (NIHSS >25): Benefit uncertain; individualize (Class 2b)
  • Mild but disabling: Reasonable to treat (Class 2a)
  • Mild non-disabling (e.g., isolated sensory): NOT recommended — no superiority vs DAPT in PRISMS trial (Class 3: No Benefit)

🔹 Clinical Relevance: Defining “Disabling”

  • NIHSS score alone does not define disability
  • A deficit that is disabling for one person may not be for another
  • Examples of disabling low-NIHSS deficits: isolated leg weakness preventing walking (NIHSS 2), aphasia in professional speaker
  • Examples of non-disabling deficits: isolated facial droop, mild sensory symptoms

Special Populations

Antiplatelet Use

2026 Guideline: IVT is recommended despite prior single or dual antiplatelet therapy (Class 1, B-NR). Although sICH risk is increased compared to no antiplatelet use, net benefit persists.

Cerebral Microbleeds

2026 Guideline:

  • Unknown CMB burden: Do NOT delay IVT for MRI (Class 1)
  • 1–10 CMBs: IVT reasonable (Class 2a)
  • >10 CMBs: Benefit uncertain; may increase sICH (Class 2b)

Pediatric Patients

2026 Guideline: In pediatric patients (28 days–18 years) with confirmed AIS presenting within 4.5h with disabling deficits, IVT with alteplase may be considered (Class 2b, C-LD). Safe but efficacy uncertain.

Choice of Thrombolytic Agent

2026 Paradigm Shift: Tenecteplase 0.25 mg/kg is now formally equivalent to alteplase (Class 1, Level A) based on >6000 patients in multiple phase 3 trials (AcT, TRACE-2, TASTE, ATTEST-2, ORIGINAL).

🔹 Tenecteplase vs Alteplase

Feature Tenecteplase Alteplase
Dose 0.25 mg/kg (max 25 mg) 0.9 mg/kg (max 90 mg)
Administration Single bolus (5–10 sec) 10% bolus + 1h infusion
Efficacy Noninferior Reference standard
sICH Similar Similar
2026 COR Class 1, Level A Class 1, Level A

Practical advantage: TNK’s single bolus simplifies drip-and-ship protocols, mobile stroke units, and transfer logistics.

Summary: Evolution of IVT Eligibility

Parameter Original (1995–2008) Prior Guidelines (2018–2019) 2026 Guidelines
Time window 0–3h 0–4.5h (+ extended windows) 0–4.5h standard; 4.5–24h select patients
Age limit >80 excluded (3–4.5h) No upper limit No upper limit
Thrombolytic agent Alteplase only Alteplase (TNK in trials) TNK 0.25 mg/kg = alteplase (Class 1)
Unknown onset Excluded MRI mismatch (2a) Class 2a (B-R)
4.5–9h window Not available Perfusion mismatch (2a) Class 2a (B-R)
4.5–24h LVO (no EVT) Not available Not addressed Class 2b (B-R)
Mild non-disabling Relative exclusion Not beneficial Class 3: No Benefit
CMB guidance Not addressed Limited guidance Explicit: 1-10 OK, >10 uncertain
Pediatric Excluded Limited data Class 2b (C-LD)

Conclusion

The 2026 guidelines represent the culmination of 30 years of progress in acute stroke reperfusion. The modern approach emphasizes tissue and clinical viability over rigid time rules. Imaging selection with MRI or CT perfusion, patient-centered evaluation of risks and benefits, and the formal endorsement of tenecteplase as equivalent to alteplase continue to expand access to reperfusion therapy for appropriate patients.

References

  1. Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2026.
  2. NINDS tPA Stroke Study Group. N Engl J Med. 1995;333:1581–1587.
  3. Hacke W, et al. ECASS III. N Engl J Med. 2008;359:1317–1329.
  4. Thomalla G, et al. WAKE-UP. N Engl J Med. 2018;379:611–622.
  5. Ma H, et al. EXTEND. N Engl J Med. 2019;380:1795–1803.
  6. Menon BK, et al. AcT Trial. Lancet. 2022;400:161–169.
  7. Wang Y, et al. TRACE-2. Lancet. 2023;401:645–654.